Scientists Engineer Human Stomach Cells to Produce Insulin for Type 1 Diabetes Treatment
Key Insights
Researchers successfully engineered human stomach organoids to produce insulin-secreting cells that resemble pancreatic beta cells (search) when transplanted into mice.
The engineered cells helped control blood sugar levels and ameliorated diabetes (search) in diabetic mouse models after activation of genetic reprogramming factors.
This approach could potentially offer an autologous cell therapy for type 1 diabetes (search) patients using their own stomach cells, avoiding immune rejection issues.
Scientists have achieved a breakthrough in type 1 diabetes (search) research by successfully engineering human stomach cells to produce insulin, offering a potential new therapeutic approach that could bypass immune rejection challenges. The collaborative research, led by teams from Weill Cornell Medicine, Peking University (search), Harvard University, and Jiangnan University (search), demonstrates that human gastric organoids can be reprogrammed to function as insulin-secreting cells when transplanted into mice.
Novel Approach to Beta Cell Replacement
Type 1 diabetes (search) affects an estimated 9.5 million people worldwide and is characterized by the immune system's selective destruction of pancreatic beta cells (search), resulting in insufficient insulin production. Current treatment approaches involving transplantation of insulin-secreting islets face significant hurdles including donor scarcity and immune rejection, requiring immunosuppression that poses additional health risks.
The research team, building on previous work that demonstrated similar capabilities in mouse stomach cells, engineered human embryonic stem cells to create transplantable human gastric organoids. These microscopic structures, resembling "mini-stomachs" in both structure and cellular composition, were designed with a controllable genetic switch system.
Genetic Engineering and Transplantation Results
The organoids were genetically engineered to express three pancreatic reprogramming factors—NEUROG3 (search), PDX1 (search), and MAFA (search), collectively called NPM—in the presence of doxycycline. After transplantation into the abdominal region of highly immunocompromised mice, the organoids survived and matured for up to six months, establishing connections with surrounding tissues and the blood system.
Upon activation of the NPM "genetic switch," the human stomach cells were successfully converted to insulin-secreting cells that resembled pancreatic beta cells (search) in both gene and protein expression profiles. The transformed cells demonstrated functional insulin production capabilities within the murine hosts.
Therapeutic Efficacy in Diabetic Models
When the experiments were conducted using diabetic mouse models, the engineered human cells secreted insulin into the bloodstream and effectively ameliorated hyperglycemia (search), a hallmark of the metabolic condition. The insulin secreted from the transformed human cells helped control blood sugar levels and improved diabetes (search) management in the test subjects.
Clinical Implications and Future Directions
The researchers emphasize that their study "provides proof of principle that human stomach tissue can be reprogrammed in vivo to produce functional insulin-secreting cells, laying the foundation for future development of an autologous, in situ therapeutic strategy for type 1 diabetes (search)."
The potential for using a patient's own stomach cells to generate insulin-producing cells could represent a significant advancement in diabetes (search) treatment, as it would eliminate the risk of immune rejection associated with current transplantation approaches. This autologous approach could provide a more sustainable and safer alternative to existing cell replacement therapies.
However, the researchers acknowledge that substantial additional research is necessary to assess the safety and efficacy of this approach before it can be considered for clinical application in human patients. The transition from successful mouse model studies to human therapeutic applications will require extensive safety evaluations and clinical trials to ensure the approach's viability and safety profile.